Nk Cell Therapy Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd.

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Nk Cell Therapy pipeline constitutes 100+ key companies continuously working towards developing 185+ Nk Cell Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Nk Cell Therapy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nk Cell Therapy Market.

The Nk Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Nk Cell Therapy Pipeline Report: https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Nk Cell Therapy treatment therapies with a considerable amount of success over the years.
• Nk Cell Therapy companies working in the treatment market are ONK Therapeutics, Catamaran Bio, Chimeric Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others, are developing therapies for the Nk Cell Therapy treatment
• Emerging Nk Cell Therapy therapies in the different phases of clinical trials are- ONKT102, CAT-179, CHM 0201, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others are expected to have a significant impact on the Nk Cell Therapy market in the coming years.
• In August 2022, Innate Pharma SA announced that a planned futility interim analysis of the INTERLINK-1 Phase III studysponsored by AstraZeneca (LSE/STO/Nasdaq: AZN) did not meet a pre-defined threshold for efficacy. Based on thisresult and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate thatthe study will be discontinued. There were no new safety findings. AstraZeneca plan to share the data in due course.
• In June 2022, SMT bio Co., Ltd. Initiated a randomized, placebo-controlled, open-label,phase IIb clinical trial to evaluate the antitumor activity of combination therapy of SMT-NK and pembrolizumab vs. pembrolizumab monotherapy in patients with advanced Biliary Tract Cancer
• In February 2022, AstraZeneca initiated a Phase III, randomized, double-blind, multicentre,international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab(MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III),unresectable NSCLC, who have not progressed following platinum-based cCRT.

Nk Cell Therapy Overview
Natural killer cells, usually referred to as NK cells, are an important subset of lymphocytes that make up the innate immune system. They are extremely specialised predators that have a significant impact on how the host rejects tumours and virally infected cells.

Get a Free Sample PDF Report to know more about Nk Cell Therapy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Nk Cell Therapy Drugs Under Different Phases of Clinical Development Include:
• ONKT102: ONK Therapeutics
• CAT-179: Catamaran Bio
• CHM 0201: Chimeric Therapeutics
• GDA-201: Gamida-Cell
• AB 101: Artiva Biotherapeutics
• DF1001: Dragonfly therapeutics
• AFM13: Affimed
• Evencaleucel: XNK Therapeutics
• GTA002: Glycostem
• BVAC-C: CELLID
• SMT-NK: SMT bio Co., Ltd.
• Monalizumab: Innate Pharma

Nk Cell Therapy Route of Administration
Nk Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Nk Cell Therapy Molecule Type
Nk Cell Therapy Products have been categorized under various Molecule types, such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Nk Cell Therapy Pipeline Therapeutics Assessment
• Nk Cell Therapy Assessment by Product Type
• Nk Cell Therapy By Stage and Product Type
• Nk Cell Therapy Assessment by Route of Administration
• Nk Cell Therapy By Stage and Route of Administration
• Nk Cell Therapy Assessment by Molecule Type
• Nk Cell Therapy by Stage and Molecule Type

DelveInsight's Nk Cell Therapy Report covers around 185+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Nk Cell Therapy product details are provided in the report. Download the Nk Cell Therapy pipeline report to learn more about the emerging Nk Cell Therapy therapies at:
https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Nk Cell Therapy Therapeutics Market include:
Key companies developing therapies for Nk Cell Therapy are - Therapeutics, Dragonfly Therapeutics, Dynavax, Exacis Biotherapeutics,, Fate Therapeutics, Feldan Therapeutics, Five Prime Therapeutics, Glycostem, Glycostem Therapeutics (IPD Therapeutic), Green Cross Corporation, GT Biopharma, HiberCell, iCell Gene Therapeutics, ImmunityBio, Innate Pharma, Kiadis Pharma, Kuur Therapeutics (Formerly Cell Medica), Multimmune GmbH, Abivax, Acepodia, Affimed Therapeutics AG, Agenus, Allife Medical Science and Technology, Artiva Biotherapeutics, Asclepius Technology Company Group, Bellicum Pharmaceuticals, Bright Path Biotherapeutics, Bristol-Myers Squibb, Cantargia, CARsgen therapeutics, Celgene Corporation/Celularity, Cellid Company, Celularity, Celyad Oncology, Chongqing Sidemu Biotechnology, CiMass, CureTech, CytoImmune Therapeutics, CytoVac, Cytovia Therapeutics, Dragonfly Therapeutics, Dynavax, Exacis Biotherapeutics,, Fate Therapeutics, Feldan Therapeutics, Five Prime Therapeutics, Glycostem, Glycostem Therapeutics (IPD Therapeutic), Green Cross Corporation, GT Biopharma, HiberCell, iCell Gene Therapeutics, ImmunityBio, Innate Pharma, Kiadis Pharma, Kuur Therapeutics (Formerly Cell Medica), Multimmune GmbH, NantKwest, Nektar Therapeutics, NKMax, ONK Therapeutics, Orgenesis, PersonGen BioTherapeutics (Suzhou), Surface Oncology, Synimmune, Vycellix, XNK Therapeutics, and others.

Nk Cell Therapy Pipeline Analysis:
The Nk Cell Therapy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Nk Cell Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nk Cell Therapy Treatment.
• Nk Cell Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Nk Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nk Cell Therapy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Nk Cell Therapy drugs and therapies-
https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Nk Cell Therapy Pipeline Market Drivers
• Increase in clinical and pre-clinical research with positive results, increase in collaborations and acquisitions between companies, increasing interest towards NK Cell Therapies among biotech and pharma companies, enhanced efficacy of NK Cells are some of the important factors that are fueling the Nk Cell Therapy Market.

Nk Cell Therapy Pipeline Market Barriers
• However, short life span, cumbersome preparation method of CAR NK cells, difficulties with NK cells and other factors are creating obstacles in the Nk Cell Therapy Market growth.

Scope of Nk Cell Therapy Pipeline Drug Insight
• Coverage: Global
• Key Nk Cell Therapy Companies: ONK Therapeutics, Catamaran Bio, Chimeric Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others
• Key Nk Cell Therapy Therapies: ONKT102, CAT-179, CHM 0201, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others
• Nk Cell Therapy Therapeutic Assessment: Nk Cell Therapy current marketed and Nk Cell Therapy emerging therapies
• Nk Cell Therapy Market Dynamics: Nk Cell Therapy market drivers and Nk Cell Therapy market barriers

Request for Sample PDF Report for Nk Cell Therapy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Nk Cell Therapy Report Introduction
2. Nk Cell Therapy Executive Summary
3. Nk Cell Therapy Overview
4. Nk Cell Therapy- Analytical Perspective In-depth Commercial Assessment
5. Nk Cell Therapy Pipeline Therapeutics
6. Nk Cell Therapy Late Stage Products (Phase II/III)
7. Nk Cell Therapy Mid Stage Products (Phase II)
8. Nk Cell Therapy Early Stage Products (Phase I)
9. Nk Cell Therapy Preclinical Stage Products
10. Nk Cell Therapy Therapeutics Assessment
11. Nk Cell Therapy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Nk Cell Therapy Key Companies
14. Nk Cell Therapy Key Products
15. Nk Cell Therapy Unmet Needs
16 . Nk Cell Therapy Market Drivers and Barriers
17. Nk Cell Therapy Future Perspectives and Conclusion
18. Nk Cell Therapy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Nk Cell Therapy Market https://www.delveinsight.com/report-store/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Nk Cell Therapy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.